Back to Search

Ozanimod vs Fingolimod for Relapsing Remitting MS

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Recruiting Phase 3 Interventional Study
Multiple Sclerosis, Relapsing-Remitting
More trials: Multiple Sclerosis clinical trials· Multiple Sclerosis trials in California
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
10 – 17
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
194 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Who this trial is looking for

This trial is looking for children and adolescents with relapsing remitting multiple sclerosis (MS). Participants will take either ozanimod or fingolimod and help researchers understand how well these treatments work and their effects on the body.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with multiple sclerosis.
  • I have had at least 1 MS relapse in the past year.
  • I have had at least 2 MS relapses in the past 2 years.
  • I have evidence of MS lesions on MRI within the last 6 months.
  • I have an EDSS score between 0 and 5.5.

You may not be able to join if

  • I have been diagnosed with progressive forms of MS.
  • I have an active or chronic disease of the immune system other than MS.
  • I have a relevant cardiovascular disease.
  • I have a relevant liver disease.
  • I have a relevant neurological disease.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Has a diagnosis of multiple sclerosis (MS) as defined by the 2017 revision of the McDonald Criteria with a relapsing remitting course of disease. * Meets at least 1 of the following criteria for disease activity: i) At least 1 MS relapse/attack in the previous year prior to…
Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286

Clinical.Trials@bms.com

CONTACT

First line of the email MUST contain NCT # and Site #.

CONTACT

NCT ID: NCT06408259 Source: ClinicalTrials.gov